Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

a new oral GLP-1 drug expected to compete directly with Novo’s Wegovy. In Q4 2024, Eli Lilly’s top-performing drugs included Mounjaro, which saw a 60% increase in revenue, and Zepbound ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

Novo Nordisk last week reported a 29 per cent increase in fourth-quarter earnings to 28.23 billion Danish kroner ($6.3 billion) as sales of Wegovy jumped 107 per cent year-on-year. Eli Lilly on ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.